Skip to main content
18301 search results for:

Dopamine Agonist 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 13-03-2024 | Dopamine Agonist | Erratum

    Correction: Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study

  2. 12-02-2024 | Dopamine Agonist | OriginalPaper

    Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study

    Prolactinomas are the most frequent functioning pituitary adenomas and account for approximately half of all pituitary adenomas [ 1 , 2 ]. Dopamine agonists (DAs) are currently the treatment of choice for prolactinoma management, leading to …

  3. Open Access 18-03-2024 | Cabergoline | Online First

    Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center

    Prolactinomas represent the most common cause of hyperprolactinemia and account for 40% of all pituitary adenomas [ 1 ]. Prolactinoma has a prevalence of 60–100 cases/million, and it is more common in women, especially those aged 20 to 50 years [ 2 …]. In women, hyperprolactinemia is a frequent cause of anovulatory cycles and infertility, but fertility can often be restored by treatment with dopamine agonists (DAs) [

  4. 11-12-2023 | Prolactinoma | Erratum

    Correction: Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review

  5. 08-11-2023 | Prolactinoma | Report

    Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review

    Prolactinomas correspond to 40% of all pituitary tumors and almost 70% of them occur in women, usually microadenomas [ 1 ]. In men, on the other hand, macroadenomas are more frequent, not related to a delay in diagnosis, but to a high frequency of …

  6. Open Access 01-12-2023 | Prolactinoma | OriginalPaper

    Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature 

    Prolactinomas account for 30–60% of pituitary tumors [ 1 , 2 ] and occur in 44.4–62.7 per 100,000 patients in cross-sectional studies [ 2 , 3 ]. Dopamine agonists (DA) are the drugs of choice to treat prolactinomas. DA normalize prolactin (PRL) …

  7. 12-05-2023 | Bromocriptine | ReviewPaper

    Dopamine 2 agonists for the management of type 2 diabetes: a systematic review and meta-analysis

    Diabetes mellitus (DM) is a group of metabolic diseases that lead to high levels of blood glucose, which occur when the body does not make any or enough insulin or does not use insulin [ 1 ]. Uncontrolled diabetes frequently results in chronic …

  8. 13-09-2023 | Piribedil | Online First

    Correction to: Role of dopamine agonists in Parkinson's disease therapy

  9. 09-11-2022 | Prolactinoma | OriginalPaper

    Metabolic effects of dopamine-agonists treatment among patients with prolactinomas

    Prolactinoma is one of the most prevalent pituitary adenomas affecting about 40% of all pituitary adenoma patients [ 1 ]. It is speculated that high prolactin (PRL) level is associated with the increased risk of cardiovascular morbidity, and …

  10. Open Access 01-12-2022 | Prolactinoma | OriginalPaper

    The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study

    Dopamine receptor agonist drugs (DAs) are the preferred treatment for pituitary prolactinoma, and they have been shown to reduce serum prolactin levels and shrink pituitary adenoma [ 1 ]. At present, the most commonly used drugs are bromocriptine …

  11. Open Access 01-12-2022 | Dopamine Agonist | OriginalPaper

    Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis

    Prolactinomas are the most common type of hormone-secreting pituitary tumors and they represent 40% of all pituitary tumors [ 1 ]. Dopamine agonists (DAs), including bromocriptine and cabergoline, are recommended as the first-line treatment for …

  12. 06-07-2022 | Erectile Dysfunction | OriginalPaper

    Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists

    Prolactinoma is the most common type of pituitary adenomas, with a prevalence of 44.4 cases per 100,000 population [ 1 ]. It is more common in women and typically presents during the reproductive age as small adenomas (< 1 cm) [ 2 ].

  13. 01-12-2021 | Prolactinoma | OriginalPaper

    Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study

    Prolactinomas, the most common type of pituitary adenomas (PAs), account for 32–66% of PAs [ 1 ]. Due to excessive secretion of prolactin, prolactinoma patients usually show typical hyperprolactinemia symptoms. Classical endocrine disorders in …

  14. Open Access 01-12-2021 | Prolactinoma | OriginalPaper

    The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas

    Prolactinomas are among the most common intracranial tumours. Prolactin secretion can lead to menstrual and lactation disorders in women and a decline in sexual function in men, and the incidence in women is significantly higher than that in men.

  15. Open Access 01-12-2021 | Hyperprolactinemia | OriginalPaper

    Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine

    The ergot-derived dopamine agonist cabergoline are thought to induce fibrotic changes in valve leaflets. Bromocriptine is perceived as a safe cardiovascular alternative to cabergoline, but the knowledge on which this is based is sparse. In our …

  16. Open Access 01-12-2021 | Prolactinoma | OriginalPaper

    The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis

    Pituitary adenomas are one of the most common intracranial tumors, and approximately half of these tumors are hormone-secreting [ 1 ]. Prolactinoma are the most common pituitary adenomas, accounting for 70–80% of all endocrine-secreting pituitary …

  17. 11-05-2023 | Parkinson's Disease | ReviewPaper

    Role of dopamine agonists in Parkinson's disease therapy

    Dopamine agonists are an important component of Parkinson's therapy. When weighing up the various therapy options, therapy with levodopa has recently been increasingly preferred due to its stronger efficacy and the ostensibly lower rate of side …

  18. 07-04-2023 | Nausea | ReviewPaper

    How to manage intolerance to dopamine agonist in patients with prolactinoma

    Prolactinomas are the most common cause of pituitary adenomas. Unlike other benign pituitary tumors, their gold-standard treatment is dopamine agonists (DA). Cabergoline (CAB) is the first choice due to its higher efficacy and better tolerability …

  19. Open Access 01-08-2021 | Dopamine Agonist | OriginalPaper

    Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study

    Impulse control disorders (ICDs) are psychopathological conditions characterized by difficulty resisting urges to engage in behaviors that are excessive and potentially harmful to oneself or others [ 1 ]. These disorders can cause significant …

  20. 01-12-2020 | Pituitary Adenoma | Original Research

    Predictors of dopamine agonist resistance in prolactinoma patients

    Pituitary adenomas are benign neuro-endocrine tumours and represent 10% of all intracranial tumours. The most common hormone-secreting pituitary tumours are prolactinomas, accounting for approximately 40% [ 1 – 3 ]. Prolactin (PRL) secreting …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.